Interactions between stem cells and their microenvironment, or niche, are essential for stem cell maintenance and function. Our knowledge of the niche for the skeletal muscle stem cell, i.e., the satellite cell (SC), is incomplete. Here we show that 1integrin is an essential niche molecule that maintains SC homeostasis, and sustains the expansion and self-renewal of this stem cell pool during regeneration. We further show that 1-integrin cooperates with fibroblast growth factor 2 (Fgf2), a potent growth factor for SCs, to synergistically activate their common downstream effectors, the mitogen-activated protein (MAP) kinase Erk and protein kinase B (Akt). Notably, SCs in aged mice show altered 1-integrin activity and insensitivity to Fgf2. Augmenting 1-integrin activity with a monoclonal antibody restores Fgf2 sensitivity and improves regeneration after experimentally induced muscle injury. The same treatment also enhances regeneration and function of dystrophic muscles in mdx mice, a model for Duchenne muscular dystrophy. Therefore, 1-integrin senses the SC niche to maintain responsiveness to Fgf2, and this integrin represents a potential therapeutic target for pathological conditions of the muscle in which the stem cell niche is compromised. npg
Sarcopenia, the slow progressive loss of skeletal muscle mass concomitant with advancing age, affects elderly people. Age-related muscle wasting is characterized by loss of muscle quantity and quality due to changes in muscle metabolism, function and regeneration 1 . The poor regeneration of aged muscle is not attributed solely to the loss of stem cells (i.e., satellite cells (SCs)) 2,3 , although SC numbers decline during aging in mice and humans. Instead, the impaired regeneration is linked to aged-related changes in both extrinsic systemic and local environments, as well as to intrinsic defects [4] [5] [6] [7] [8] [9] [10] [11] .
Fgf2, a well-studied niche signal, has important roles in driving SC proliferation. SCs are maintained in a quiescent state by repressing Fgf2 signals 7 . Aging increases the level of Fgf2 in skeletal muscle and decreases the level of the FGF signaling inhibitor Spry1 in SCs, which results in loss of a portion of the SC pool owing to breaking quiescence 2 . Paradoxically, aged SCs are nonresponsive to Fgf2 during their proliferation and self-renewal 9 . Inhibiting FGF signaling in aged SCs rescues the quiescent phenotype at the expense of regeneration 2 , whereas ectopically activating Fgf receptor 1 (Fgfr1) rescues the proliferative capacity of aged SCs 9 . It is unclear what underlies the differential requirement for FGF and what causes the desensitization of Fgfr1, but changes in interactions with other cell surface proteins may have a role.
Integrins adhere to the extra cellular matrix (ECM) to cooperate with different growth factor signaling pathways, depending on the cell type and context 12, 13 . Integrins are heterodimers, comprised of an αand a β-chain, that function to link the ECM to the actin cytoskeleton 14 . There are 18 αand 8 β-chains, which can form at least 28 isoforms. Of particular relevance to skeletal muscles are α7and α5integrins and laminin-α2, as mutations in their genes cause muscular dystrophies 14, 15 . Inactivation of Itgb1 (which encodes β1-integrin) in the embryonic muscle lineage causes defects in muscle cell migration, fusion and sarcomere assembly, but not in progenitor proliferation 16 . Although β1-integrin is conspicuously expressed by adult SCs, its role in these cells has not been examined, especially with respect to modulating FGF signaling. Here we show that β1-integrin is the sensor of the SC niche that maintains quiescence of SCs during homeostasis and that it also cooperates with FGF signaling to promote SC proliferation and renewal after injury. We further demonstrate that activating β1integrin signaling restores FGF sensitivity in aged SCs and improves muscle regeneration. Activating β1-integrin in the mdx mouse 17 can also promote SC expansion and improve function. We propose that β1-integrin is a potential therapeutic target of pathological conditions in which the SC niche is compromised.
RESULTS

SCs without b1-integrin cannot maintain quiescence
To define the function of β1-integrin in adult SCs, we used a Pax7 Cre-ERT2(CE) driver 18 , in which the first exon of Pax7 was replaced by Cre-ER T2 , for tamoxifen (tmx)-inducible gene inactivation of an Itgb1 conditional allele (Itgb1 f ) 19 in SCs. The ROSA26 reporter alleles (R26R YFP or R26R LacZ ), which express either yellow fluorescent protein (YFP) or β-galactosidase (LacZ) from the ubiquitously expressed ROSA26 locus under the control of Cre, were included for lineage marking and for assessing recombination efficiency ( Supplementary  Fig. 1a-c) 18 . Three days after administering the tmx regimen, YFP + conditional-mutant (Itgb1 −/− ) SCs no longer had detectable β1-integrin ( Supplementary Fig. 1d,e ) but maintained Pax7 expression, as compared to control SCs (Fig. 1a) . To assess whether a r t i c l e s 8 9 0 VOLUME 22 | NUMBER 8 | AUGUST 2016 nature medicine β1-integrin loss affected SC niche occupancy, we followed lineage-marked cells up to 180 d ( Fig. 1b-d) . The number of Itgb1 −/− SCs was unchanged 7 d after administering the tmx regimen, as compared to that in control cells, but it was reduced to about half of that in the control cells at 21 d after tmx treatment. The number of Itgb1 −/− SCs continued to decline over time, but the SCs were not completely lost at 180 d after tmx treatment. We did not detect programmed cell death (PCD) of Itgb1 −/− SCs at these time points ( Supplementary Fig. 1f ).
Instead, experiments with lineage-labeled myofibers suggested that the number of mutant SCs declined due to differentiation and incorporation into existing muscle fibers ( Fig. 1b,c) .
To test whether the slow loss in the numbers of SCs was indeed due to spurious activation and differentiation, we performed continuous administration of 5-bromo-2′-deoxyuridine (BrdU) for 30 d. A significant portion of Itgb1 −/− SCs incorporated BrdU during this period, revealing aberrant cell cycle entry ( Fig. 1e) . A greater fraction of cells that express MyoD, a major regulator of muscle differentiation, was also detected in the mutant SCs than in the control SCs ( Fig. 1f) , supporting the hypothesis of spurious differentiation. Given that there was no increase in the number of SCs, those that became activated probably had limited proliferative capacity. Furthermore, the cell polarity proteins cadherin 15 (Cdh15; also known as m-cadherin) and par-3 family cell polarity regulator (Pard3) were not localized appropriately in Itgb1 −/− SCs ( Supplementary Fig. 2 ), suggesting that loss of mutant SCs is associated with polarity defects. We conclude that β1-integrin senses the quiescent SC niche to maintain polarity and to prevent spurious activation and differentiation.
SCs without b1-integrin cannot sustain proliferation after injury
To assess whether Itgb1 −/− SCs could support regeneration, we conducted muscle-injury experiments, using cardiotoxin (CTX), at 3 d after tmx treatment ( Supplementary Fig. 3a ). We performed these and all subsequent assays at this time point because the mutant SC number had not yet decreased, allowing us to appropriately analyze the separate role of β1-integrin in SC-driven muscle regeneration. Severely defective regeneration was observed at 5, 10 and 30 d after CTX-mediated injury ( Fig. 1g-i and Supplementary Fig. 3b-d) . Consistent with studies in embryos 16 , adult Itgb1 −/− myoblasts migrated and fused poorly in vitro (Supplementary Fig. 3e-g) , which explains the reduced diameter of the regenerated fibers (Fig. 1i) .
The drastic reduction in the number of regenerated fibers ( Fig. 1h ) in the mutant muscle suggested a defect in the ability of the SCs to expand. To test this, we pulsed proliferating cells with npg 5-ethynyl-2′-deoxyuridine (EdU) from day 2 to day 5 daily after treatment with CTX. Itgb1 −/− SCs proliferated normally at day 2, but they did not sustain the same proliferative rates as control SCs over time ( Fig. 2a,b) . Although PCD did not appear to be a contributor to the reduced number of mutant cells ( Supplementary Fig. 1f ), we cannot exclude other cell-elimination processes. To ascertain the molecular changes in Itgb1 −/− SCs, we performed cell cycle analyses of FACS-isolated YFP + control and mutant SCs 20 in culture ( Fig. 2c-f ).
As compared to control cells, mutant cells had both lower levels of cyclins D1 and D2 and a misregulated cell cycle, showing an increased fraction of cells in the G1 phase and a decreased fraction of cells in S phase at 72 h. Gene expression profiles of control and mutant SCs showed no differences up to 24 h in culture, but they became progressively different at 48 and 72 h ( Supplementary Fig. 4) . At 72 h, many of the genes associated with muscle differentiation were upregulated in mutant cells ( Fig. 2g) . These data are consistent with the role of β1-integrin in sustaining cyclin D levels and in G1/S transition in other cell types 13, 21 .
To determine whether there was a defect in SC self-renewal, we monitored Pax7 + cells in the regenerative area, which was marked by YFP + fibers with centrally located nuclei. Pax7 + cell numbers were significantly reduced at days 3 and 4, and the cells could not be detected after day 5 ( Fig. 3a,b) . Although there were fewer MyoD + mutant cells, ratios of MyoD + to Pax7 + mutant cells were higher than those of control cells ( Supplementary Fig. 5a,b) , indicating that Itgb1 −/− SCs turned off Pax7 and failed to self-renew. Thus, β1-integrin is required for SC proliferation and self-renewal to drive muscle regeneration.
b1-integrin cross-talks with FGF signaling in SCs
Activation of integrins by the ECM cooperates with receptor tyrosine kinases (RTKs), including FGF receptors, to activate Erk MAP kinases and drive proliferation in many cell types 12, 13, [21] [22] [23] [24] . Fgf2 stimulates myoblast proliferation via the same effectors 25 , which may involve integrin signaling. We therefore examined whether Itgb1 −/− myoblasts were defective in Fgf2 responsiveness with or without fibronectin, an ECM molecule that was originally used to demonstrate integrin-RTK cross-talk 21, 24 . The phosphorylation levels of common FGF and integrin downstream signaling effectors, Erk and Akt (pErk1, pErk2 and pAkt), were assessed ( Fig. 3c,d) . Control cells responded better to Fgf2 in the presence of fibronectin; low levels of Fgf2 were sufficient to phosphorylate Erk and, to a lesser extent, Akt. In contrast, the presence of fibronectin or high levels of Fgf2 alone only weakly activated Erk and Akt. Mutant cells were indeed defective in responding to Fgf2 in the presence of fibronectin. Notably, high levels of Fgf2 could partially restore cooperativity, presumably owing to compensation by other fibronectin-binding integrins in Itgb1 −/− cells.
We next assessed the relevance of the cooperativity between integrin and FGF signaling in the SCs. By using the single-myofiber assay 9 to examine SC fates, we determined that the majority of control SCs maintained Pax7 expression (Pax7 + MyoD − and Pax7 + MyoD + ). The npg addition of Fgf2 increased the population of expanding Pax7 + MyoD + cells but did not alter the fraction of self-renewed Pax7 + MyoD − cells ( Fig. 3e,f) . In contrast, the majority of mutant SCs expressed only MyoD (Pax7 − MyoD + ) and was committed to differentiation, at the expense of Pax7 + MyoD + and Pax7 + MyoD − fractions. The fractions of the latter two populations were restored to amounts similar to those in the control by Fgf2 addition, again suggesting compensation by other integrins. Because SCs express almost all of the integrin subtypes 26 , we tested whether the RGD peptide, a broad-spectrum integrin-binding competitor that interferes with ECM engagement 14 , was sufficient to disrupt the FGF response. SCs that were treated with the RGD peptide had a reduced fraction of Pax7 + MyoD + cells, which could not be rescued by Fgf2 treatment (Supplementary Fig. 5c-e ).
Thus, RGD-binding integrins in the SCs, including those containing β1-integrin, cooperate with Fgf2. SC self-renewal has been associated with FGF stimulation of asymmetric phosphorylation of the αand β-subunits (p38-α and p38-β) of p38 MAP kinase 9, 27 . Fewer Itgb1 −/− SCs showed polarized pp38, relative to that in control cells, and Fgf2 treatment could increase the fraction of mutant SCs with polarized pp38 (Fig. 3g,h) . Taken together, we have uncovered a mechanism for β1-integrin in sustaining SC expansion and self-renewal.
Aged SCs are defective in integrin activity
The characteristics of Itgb1 −/− SCs are similar to those of aged SCs; both are gradually lost from the niche 2 , cannot sustain proliferation 28 , are committed to differentiation 5 and are defective in self-renewal 9 . Given that ECM composition 29 and stiffness 30 change in aged muscles, we wondered whether the environment has an effect on β1-integrin or overall integrin activity in aged cells, thereby desensitizing aged SCs to Fgf2 (ref. 9). To probe for changes in integrin activity in aged SCs, we first used an antibody (9EG7) that recognizes the 'high-affinity' ligand-bound active β1-integrin 31,32 on young and aged SCs. The majority of young myofiber-associated SCs showed well-aligned basal-membrane-bound β1-integrin in its active conformation, which mirrored that of total β1-integrin (compare Fig. 4a to Fig. 1a ). Despite a basally localized pattern of total β1-integrin ( Supplementary Fig. 6a ), more aged SCs showed active β1-integrin in abnormal patterns, including disorganized puncta a b +Fgf2 npg or β1-integrin that was undetectable (Fig. 4a,b) . To ascertain ageassociated changes in overall integrin activity, we monitored spatial patterns of their common effectors-integrin-linked kinase (ILK), parvin and paxillin (Fig. 4c) . ILK, parvin and paxillin were localized to the laminar side in young SCs as expected. In contrast, aged SCs showed disorganized distribution patterns of these effectors. Vinculin, which binds to actin but not directly to integrin 33 , encircled young SCs, and this pattern was slightly disorganized in aged SCs. npg VOLUME 22 | NUMBER 8 | AUGUST 2016 nature medicine Thus, aged SCs show abnormal localization of, and disparate changes in, common integrin effectors, reflecting a dysregulation of overall integrin activity. If dysregulated integrin signaling underlies the dysfunction of aged SCs, then activating β1-integrin alone may be sufficient for rescue. To test this, we injected injured muscles with a β1-integrin-activating antibody TS2/16 (ref. 34 ) and observed robust muscle regeneration in control young mice that were injected with vehicle (YV) ( Fig. 4d-f) . Treatment with the RGD peptide repressed muscle regeneration in young mice (YI). Although treatment with TS2/16 did not enhance the already robust levels of regeneration in young animals (YA), it did improve regeneration in aged mice (AA) to a level comparable to that in the young mice. As controls, we showed that TS2/16 treatment did not rescue regeneration of Itgb1 −/− muscle, but it could activate β1-integrin-dependent signaling (Supplementary Fig. 7a-d) . Regenerated muscles still had measurable improvement 30 d after injection with a single dose of TS2/16 (Supplementary Fig. 7e-g) .
To determine whether TS2/16 treatment improves SC function, we applied it to myofiber-associated aged SCs and assessed their expansion and Pax7 expression. Treatment with the IgG control, or that with TS2/16 or Fgf2 alone, did not show an effect. Treatment with TS2/16 and Fgf2 together increased the fraction of Pax7 + cells, the number of fiber-associated myogenic cells and the fraction of SCs showing polarized pp38 (Fig. 5a-c and Supplementary Fig. 8 ). Because treatment with TS2/16 alone is sufficient to improve aged muscle regeneration in vivo, we surmise that muscle damage releases a sufficient amount of Fgf2 to cooperate with TS2/16-activated β1-integrin in aged SCs. Mechanistically, we found that TS2/16 treatment increased the fraction of aged SCs on myofibers with detectable Fgfr1, relative to that after treatment with control IgG (Fig. 5d,e) . Although it not sufficient to enhance expansion, treatment with TS2/16 alone increased the proportion of aged SCs with detectable phosphorylated FGF receptors (pFGFR). Treatment with TS2/16 and Fgf2 together stimulated pFGFR in almost all of the aged SCs (Fig. 5f,g) , consistent with their dual requirement for enhancing expansion of aged SCs. Associations between FGF receptors and either α-integrins 35 or αvβ3-integrin 36 were suggested to underlie FGF-integrin cooperativity. We show here that Fgfr1 can associate with β1-integrin and that TS2/16 enhances their association (Fig. 5h) . These data indicate that TS2/16 operates at multiple layers to enhance FGF signaling and restore the responsiveness in aged SCs. npg Activating b1-integrin improves dystrophic muscles The positive effect of TS2/16 on regeneration in the environment of aged cells led us to consider whether it might be beneficial in another context of impaired muscle regeneration, namely muscular dystrophy. For this, we used the mdx mouse model, in which mice lack dystrophin expression due to a nonsense mutation in the Dmd gene 17 . Because muscle in the mdx mouse contains disorganized ECM, we anticipated that more Pax7 + SCs would reside outside of the myofiber lamina, relative to those in the control mice (C57BL/10; Supplementary  Fig. 9a-c) . Additionally, mdx SCs that were associated with myofibers showed abnormal patterns of active β1-integrin ( Supplementary  Fig. 6b,c) . We administered TS2/16 into the tibialis anterior (TA) muscle of mdx mice and found that a single dose was sufficient to promote the expansion of myogenic cells, as shown by increased EdU incorporation 3 d after treatment (Fig. 6a,b) . We extended TS2/16 treatment to four weekly injections ( Fig. 6c) and found that the crosssectional area and muscle fiber diameter were increased, relative to those in mice that were treated with control IgG (Fig. 6c-e) . Also, the percentage of Pax7 + cells outside of the myofiber lamina was reduced, reflecting an improvement in SC-niche interaction ( Supplementary  Fig. 9c-e ). Because α7β1-integrin binds to laminin, the ECM component that engages with the dystrophin complex, activating β1-integrin probably also enhances the integrity of muscle fibers in mdx mice via improving their connection to the ECM.
To determine whether the above-mentioned long-term regimen resulted in functional rescue, we compared the contractile properties of IgG-and TS2/16-treated mdx TA muscles in situ; wild-type (WT) and untreated mdx TA muscles were analyzed in parallel as references ( Fig. 6f-j) . TS2/16-treated mdx muscles had reduced cross-sectional areas, as compared to mdx and IgG-treated mdx muscles, consistent with a reversal from hypertrophic pathology. Of note, TS2/16-treated muscles showed improvements in strength, using a variety of measurements including single-twitch force, maximum isometric tetanic force, force-frequency relationship, time to fatigue and fatigue index. Activating β1-integrin may therefore be a viable therapeutic means to improving muscle repair and function in disease conditions.
DISCUSSION
Our results frame a model in which β1-integrin functions as a sensor of the SC niche, which declines in function during aging (Supplementary Fig. 10 ). Because Itgb1 −/− cells show compromised pErk induction after Fgf2 treatment, the exit from their quiescence is more likely due to cell-polarity defects than to overt FGF-Erk signaling 2 . In the context of regeneration, β1-integrin has a distinct role in cooperating with Fgf2 to drive SC proliferation and renewal. In aged muscle, changes in ECM 29, 30 impose physiologically relevant alterations in integrin activity 37 , which presumably contribute to the decline of SC sensitivity to Fgf2. The current view regarding FGF and aging SCs is puzzling. Aging SCs are sensitive to increased FGF-Erk signaling, causing quiescence break and stem cell pool depletion 2 , and yet aged SCs are insensitive to Fgf2 for proliferation in vitro 9 . Our study provides a potential explanation-a fraction of aging SCs with sufficient integrin activity cooperates with increasing amounts of Fgf2 to break quiescence and becomes lost, whereas aging SCs with dysregulated integrin activity that is insufficient to support FGF signaling remain. As such these remaining aged SCs cannot support robust regeneration after injury, unless integrin activity is re-established to restore FGF signaling, for example, by administration of TS2/16.
Although activating β1-integrin alone can improve regeneration in both aged and dystrophic muscles, it may prove more effective to target all of the integrins that are relevant to SC expansion and FGF sensitivity, such as the RGD-binding integrins. There are at least eight integrins (three of which contain β1-integrin) that bind to the RGD motif, which is the integrin-binding site of many ECM molecules, including fibronectin 14 . Although β1-integrin and fibronectin cooperate with Fgf2, we cannot exclude contributions by other RGD-containing ECM components. Conversely, because SCs express almost all of the αand β-integrins 26 , defining the contribution of each integrin in this context may involve considerable effort. Despite the complexity, our findings help to explain why ECM implantation can enhance muscle regeneration 38 . Future investigation into how the integrin-FGF axis intersects with other pathways, such as that involving the transcription factor signal transducer and activator of transcription 3 (Stat3), to regulate SC function is important. Although Stat3 expression is not changed in Itgb1 −/− SCs, Stat3 is upregulated in activated SCs 39 , and inhibiting Stat3 enhances regeneration in the contexts of aging and dystrophies 10, 11 . We would be remiss in not mentioning that, other than Fgf2, integrins can cooperate with many growth factors 12 that may also contribute to SC function. We provide here a proof-of-principle study that may be broadly applicable to muscle diseases that involve SC niche dysfunction, but further refinement is needed for this method to become a viable treatment. Given the role of integrins in other stem cell populations 19, 40 , the knowledge derived from our study should, in general, have broader implications for aging and the decline of stem cell function.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Mouse studies. Mouse experiments in this study were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the Carnegie Institution of Washington (Permit number A3861-01). The Pax7 Cre-ERT2 (also known as Pax7 CE ) allele (B6;129-Pax7 tm2.1(cre/ERT2) Fan/J) has been described 18 . The Itgb1 f allele (B6;129-Itgb1 tm1Efu /J) 19 and the R26R lacZ (B6.129S4-Gt(ROSA)26Sor tm1Sor /J) 41 and R26R YFP (B6.129X1-Gt(ROSA)26Sor tm1(EYFP) Cos/J) 42 reporter mice were obtained from the Jackson Laboratory. The experimental mice used in this study were Pax7 CE/+ ;Itgb1 f/f ; R26R LacZ/LacZ , Pax7 CE/+ ;Itgb1 f/f ;R26R YFP/YFP , or Pax7 CE/+ ;Itgb1 f/f (referred to as Itgb1 −/− ). Reporter alleles were chosen based on the assay: YFP is preferable for immunofluorescence, and necessary for live-imaging and FACS sorting, whereas LacZ is useful for histological analyses. Controls used were Pax7 CE/+ ;R26R LacZ/LacZ , Pax7 CE/+ ;R26R YFP/YFP , or Pax7 CE . For young versus aged comparisons, mice were used at 3-6 months of age (young) or 18-24 months of age (aged). For non-lineage-marked SC studies, aged C56/BL6 mice were used (JAX and NIH). Sex was mixed. For dystrophic muscle studies, C57BL/10-background control and mdx male mice (JAX) were used at 3-4 months of age.
Mice were given tamoxifen (tmx; 20 mg/ml in corn oil (Sigma)) at 3 mg per 40 g body weight per intraperitoneal injection, once a day consecutively for 5 d. All experiments, except where noted, were conducted 3 d after the final injection. For injury, mice were anesthetized using 2,2,2-tribromoethanol (Sigma), which was dissolved in 2-methyl-2-butanol (Sigma) as a 100% (wt/vol) stock solution, diluted 1:80 in PBS, and injected intraperitoneally at 10 µl per g body weight. For injury studies of Itgb1 −/− versus control mice, 50 µl of 10 µM cardiotoxin (Sigma) was injected using an insulin syringe (U-100; Becton Dickinson) into TA muscles. Animals were then harvested at the post-injury time points stated in the text and legends. For short-term daily in vivo proliferation assays, EdU (Invitrogen) was given by intraperitoneal injection at 0.1 mg per 20 g body weight per injection, at 2, 3, 4, or 5 d after injury. Animals were harvested 24 h after injection. For long-term BrdU incorporation, mice were fed with 0.8 mg/ml of BrdU in drinking water for 1 month. For labeling Pax7 + cells, both aged and young Pax7 CE ; R26R YFP/YFP mice were injected with tmx as described above and harvested for analysis or single-fiber culture. For needle-tract injury, TA muscles were injured as described previously 6 . Two days post injury, TA muscles received 6 × 10 µl anti-TLR2 (TS2/16; 10 µg/ml), 60 µl vehicle control (mouse IgG; 10 µg/ml), RGD peptide (10 µg/ml), or scrambled peptide (10 µg/ml) by intramuscular injections. Muscles were harvested 3 d after these injections for analysis. For mdx mice, 10 µg (in 25 µl) of vehicle control IgG or TS2/16 were injected to each TA muscle, either by single injection or repeated four times weekly. , and Fgfr1 (cat. no. 9740) were from Cell Signaling. Anti-Gapdh antibody was from Chemicon (MAB374). Antibodies against activated β1-integrin (9EG7) and paxillin (610619) were from BD Biosciences. For detecting β1-integrin by western blot and Pard3 in SCs on single fibers, MAB1997 and 07-330, respectively, from Millipore were used. Anti-TLR2 (TS2/16) and control mouse IgG were from Abcam (ab1119333 and ab37355, respectively). Anti-BrdU antibody was from Exalpha (A250P). GFP-specific antibodies were from Invitrogen (G10362, rabbit) and Aves (GFP-1020, chick). Antibodies against eMyHC (F1.652), MHC (MF20), and Pax7 (PAX7) were from Developmental Studies Hybridoma Bank. Anti-PAX7 of rabbit origin (PA1-117; Thermo Fisher Scientific) was also used for co-staining with antibodies of mouse origin. Anti-laminin (L9393) and anti-vinculin (V9131) were from Sigma. Antibodies against cyclin A(sc-596), cyclin B1 (sc-245), cyclin D1 (sc-717), cyclin D2 (sc-593), cyclin D3 (sc-182), cyclin E (sc-198), ILK (sc-20019), m-cadherin (sc-81471) and MyoD (sc-304) were from Santa Cruz Biotechnology. RGD and scrambled peptides were from Santa Cruz Biotechnology and AnaSpec. Carrier-free Fgf2 was purchased from R&D systems, dissolved and stored at −80 °C. The working dilution of the above antibodies and concentrations of recombinant proteins were typically used as recommended by the companies, unless otherwise specified below, or in the text and legends, in assay-dependent manners.
Muscle sample processing. TA muscles were harvested, fixed for 8 min in ice-cold 4% paraformaldehyde (EMS) in phosphate-buffered saline (PBS), incubated sequentially in 10% and 20% sucrose in PBS overnight, frozen in isopentane (Sigma) and liquid nitrogen, and stored in a −80 °C freezer until cryosectioning. Cross-sections (10 µm) were stained with hematoxylin and eosin (H&E; Surgipath), or Gomori's one-step trichrome staining kit (Polysciences), or they were subjected to X-gal (Sigma) reactions as described previously 43 or used for immunostaining and EdU reactions (see below).
Satellite cell isolation and myoblast culture. YFP-marked cells were isolated as described previously 17 . Briefly, for SC preparation, muscles were dissected and incubated in 0.2% collagenase type I (Sigma) in Dulbecco's modified Eagle's medium (DMEM; Gibco) at 37 °C with gentle shaking for 1.5 h. Muscle was then triturated in 10% FBS in DMEM, washed with PBS, and incubated in 0.2% dispase (Gibco) in DMEM at 37 °C with gentle shaking for 30 min. Cells were filtered through a 70-µm cell strainer (VWR) and subjected to cell sorting using the BD FACS ARIA III, gating first for cell size using forward and side scatter, and then for YFP fluorescence. FACS Diva (for cell isolation) software was used. Cells were then used for downstream analyses. For cell cycle analysis, migration, and programmed cell death assays, as well as for protein extracts for western blotting (see below), or for RNA isolation for RNA-seq analysis (see below) over a time course, cells were cultured in 'minimal' growth medium (10% horse serum (HS), 1% penicillin-streptomycin, 1% Glutamax in DMEM with high glucose; GIBCO) on Matrigel-coated (BD biosciences) tissue culture dishes. For differentiation and fusion, cells were cultured in medium containing 2% HS on Matrigel. For Erk and Akt signaling assays (see below), when considerably more cells were needed, cells were expanded as myoblast cultures in 'enriched' growth medium (20% FBS, 5% HS, 1% penicillin-streptomycin, 1% Glutamax (Gibco), 0.1% chick embryo extract (MP Biomedicals), and 10 ng/ml FGF (R&D systems)) on Matrigel, until sufficient cell numbers were reached, typically in 5-7 d. All cell cultures were placed in 37 °C tissue culture incubators with 5% CO 2 .
Myofibers with associated SCs were isolated from extensor digitorum longus (EDL) muscles by 1.5-h digestion in 0.2% collagenase type I in DMEM at 37 °C. The digested muscle was then transferred to tissue culture dishes containing DMEM, 1% penicillin-streptomycin, and 1% Glutamax. Live myofibers were isolated with a fire-polished glass pipette. Isolation of individual myofibers by pipette was repeated to remove dead myofibers and cellular debris. They were either immediately fixed for assays (for example, probe for activated β1-integrin) or placed in DMEM, 10% HS, 1% penicillin-streptomycin, and 1% Glutamax with daily medium and reagent changes. Please note that this minimal growth medium contains no additional additives. Depending on the assays, myofibers were cultured for different amounts of time before fixation. For Par3, pp38, Fgfr1, and pFgfr analysis, myofibers were cultured for 36 h. For self-renewal assays with Pax7 and MyoD expression, 48-to 96-h cultures were used (specified in the text or figure legend). They were either cultured with or without Fgf2 (10 ng/ml), and with or without IgG or TS2/16 (10 µg/ml). Phosphatase Inhibitor Cocktail Set II (Calbiochem) was used as directed during fixation.
For FGF and fibronectin stimulation, we modified the condition described previously for other cell types 18, 21 . On the day of the experiment, control and Itgb1 −/− myoblasts were detached by treatment with 2 mM EDTA in serum-free base medium (SFBM; high-glucose DMEM, 0.5% BSA, penicillin-streptomycin), washed twice, and cultured in SFBM on Petri dishes as cell suspensions for 2 h to minimize the residual effect of growth factors and the contact-dependent signaling from prior culture conditions. 50,000 cells were then transferred to each well of a 12-well dish containing SFBM with or without fibronectin (10 µg/ml) for 20 min. The wells were either coated with Sigma-cote (to prevent attachment) or pre-coated with fibronectin (10 µg/ml overnight). Specified concentrations of Fgf2 were then added, and cells were harvested 10 min later for western blots (see below for detailed procedure). Blots were first probed with anti-pErk1/2 and anti-pAkt, followed by HRP-conjugated secondary antibodies, and binding was then detected with ECL (Amersham). Blots were then stripped and reprobed with anti-Erk1/2 and anti-Akt. Fold of stimulation is presented as pErk/Erk and pAkt/Akt ratios relative to pErk/Erk and pAkt/Akt ratios, respectively, of control doi:10.1038/nm.4116 npg
